Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
7 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Potential best in class p roduct candidates in development for cancer & respiratory viral diseases April 2024 NASDAQ - TRAW
16 Apr 24
8-K
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
15 Aug 23
8-K
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
10 Aug 23
8-K
Other Events
21 Jul 23
8-K
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
15 May 23
8-K
Other Events
9 May 23
8-K
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
6 Apr 23
8-K
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
16 Mar 23
Registration and prospectus
D
$14.00 mm in other securities, sold $14.00 mm, 2 investors
16 Apr 24
S-3
Shelf registration
30 Jun 23
S-8
Registration of securities for employees
15 Nov 22
424B5
Prospectus supplement for primary offering
24 Sep 21
424B5
Prospectus supplement for primary offering
23 Sep 21
424B5
Prospectus supplement for primary offering
20 Aug 21
S-8
Registration of securities for employees
30 Jul 21
25-NSE
Exchange delisting
23 Jul 21
424B5
Prospectus supplement for primary offering
11 Feb 21
424B5
Prospectus supplement for primary offering
10 Feb 21
Proxies
DEFA14A
Additional proxy soliciting materials
16 Apr 24
DEFA14A
Additional proxy soliciting materials
21 Jul 23
DEF 14A
Definitive proxy
7 Jun 23
DEFA14A
Additional proxy soliciting materials
21 Jul 22
DEF 14A
Definitive proxy
25 May 22
DEFA14A
Additional proxy soliciting materials
16 Jul 21
DEFA14A
Additional proxy soliciting materials
25 Jun 21
DEF 14A
Definitive proxy
28 May 21
DEFA14A
Additional proxy soliciting materials
1 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Mar 21
Other
EFFECT
Notice of effectiveness
12 Jul 23
UPLOAD
Letter from SEC
7 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
EFFECT
Notice of effectiveness
19 May 20
CORRESP
Correspondence with SEC
15 May 20
CORRESP
Correspondence with SEC
15 May 20
UPLOAD
Letter from SEC
7 May 20
SEC STAFF
SEC staff action: Order
19 Feb 20
SEC STAFF
SEC staff action: Order
7 Feb 20
EFFECT
Notice of effectiveness
22 Nov 19
Ownership
3/A
Initial statement of insider ownership (amended)
12 Apr 24
3/A
Initial statement of insider ownership (amended)
11 Apr 24
SC 13D
Viriom, Inc.
8 Apr 24
4
Robert Redfield
3 Apr 24
4
Charles David Pauza
3 Apr 24
4
WERNER CAUTREELS
3 Apr 24
4
Nikolay Savchuk
3 Apr 24
4
Iain D. Dukes
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24